Cerity Partners LLC Purchases 295 Shares of Eli Lilly and Company (NYSE:LLY)

Cerity Partners LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 0.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 580,815 shares of the company’s stock after purchasing an additional 295 shares during the period. Eli Lilly and Company accounts for 1.0% of Cerity Partners LLC’s investment portfolio, making the stock its 15th biggest position. Cerity Partners LLC owned about 0.06% of Eli Lilly and Company worth $453,197,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Sierra Summit Advisors LLC grew its holdings in shares of Eli Lilly and Company by 19.4% during the fourth quarter. Sierra Summit Advisors LLC now owns 10,856 shares of the company’s stock worth $8,381,000 after purchasing an additional 1,767 shares in the last quarter. Trek Financial LLC grew its stake in Eli Lilly and Company by 20.4% in the 4th quarter. Trek Financial LLC now owns 2,296 shares of the company’s stock worth $1,773,000 after buying an additional 389 shares in the last quarter. Polymer Capital Management HK LTD increased its holdings in shares of Eli Lilly and Company by 891.6% in the 4th quarter. Polymer Capital Management HK LTD now owns 4,958 shares of the company’s stock worth $3,828,000 after buying an additional 4,458 shares during the last quarter. Edgewood Management LLC raised its position in shares of Eli Lilly and Company by 13.0% during the 4th quarter. Edgewood Management LLC now owns 2,547,982 shares of the company’s stock valued at $1,967,042,000 after buying an additional 292,150 shares in the last quarter. Finally, Titleist Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 9.4% during the 4th quarter. Titleist Asset Management LLC now owns 511 shares of the company’s stock worth $394,000 after acquiring an additional 44 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Bank of America reiterated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Trading Down 6.5 %

NYSE LLY opened at $737.56 on Monday. The stock has a market cap of $699.33 billion, a P/E ratio of 62.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $692.96 and a fifty-two week high of $972.53. The stock has a 50 day simple moving average of $848.36 and a two-hundred day simple moving average of $831.41. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a share buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.